BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BXYData from more than 2,600 agitation episodes collected
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
BXYAchieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates
BXYTopline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August
